Century Therapeutics, Inc. (IPSC)
$1.38-4.17%Close
SELLCRISIS · day 20
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $119M
- Beta
- 1.67
- P/E (TTM)
- -1.33
- Short % float
- 60.06%
- Days to cover
- 50.9
- SI change
- -0.5%
- 1W
- +4.55%
- 1M
- -31.00%
- vs SPY 1W
- +4.68%
- vs SPY 1M
- -33.51%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 15
- VALUE
- 15
- GROWTH
- 45
- GARP
- 8
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-31.7%
REV YoY-
ROE-52.8%
EPS YoY-
ROA-38.3%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-1.33
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.22
P/FCF-
EV/EBITDA-2.54
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E14.90
ALTMAN Z-
CURR RATIO8.28
ND/EBITDA-
BETA1.67
Company news
FAQ
- What is LOPJLB’s current signal on IPSC?
- LOPJLB’s latest quantitative signal on Century Therapeutics, Inc. (IPSC) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IPSC in?
- Century Therapeutics, Inc. (IPSC) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Century Therapeutics, Inc. (IPSC) do?
- Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell ly…